Symbiotix Biotherapies Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Symbiotix Biotherapies General Information

Description

Developer of a novel class of molecular therapeutics intended to treat inflammatory bowel disease. The company's novel class of molecular therapeutics are oral agents based on molecules derived from the human microbiom which are used for multiple sclerosis and other serious immune-mediated diseases, enabling patients to improve their lives and treat inflammatory disaeses.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • One International Place
  • Suite 1400
  • Boston, MA 02110
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • One International Place
  • Suite 1400
  • Boston, MA 02110
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Symbiotix Biotherapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 01-Oct-2019 Completed Out of Business
5. Later Stage VC (Series A) 01-Nov-2017 Completed Generating Revenue
4. Grant 21-Sep-2016 Completed Startup
3. Later Stage VC Completed Startup
2. Grant 01-Jun-2015 $2.98M Completed Startup
1. Grant 15-Jul-2014 $720K Completed Startup
To view Symbiotix Biotherapies’s complete valuation and funding history, request access »

Symbiotix Biotherapies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3
Series A2
Series A1 303,796 $0.001000 $7.9 $7.9 1x $7.9 10.88%
To view Symbiotix Biotherapies’s complete cap table history, request access »

Symbiotix Biotherapies Patents

Symbiotix Biotherapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2013019896-A1 Platform for identifying and/or characterizing immunomodulatory agents Inactive 01-Aug-2011

Symbiotix Biotherapies FAQs

  • When was Symbiotix Biotherapies founded?

    Symbiotix Biotherapies was founded in 2009.

  • Where is Symbiotix Biotherapies headquartered?

    Symbiotix Biotherapies is headquartered in Boston, MA.

  • What industry is Symbiotix Biotherapies in?

    Symbiotix Biotherapies’s primary industry is Drug Discovery.

  • Is Symbiotix Biotherapies a private or public company?

    Symbiotix Biotherapies is a Private company.

  • What is Symbiotix Biotherapies’s current revenue?

    The current revenue for Symbiotix Biotherapies is .

  • How much funding has Symbiotix Biotherapies raised over time?

    Symbiotix Biotherapies has raised $5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process